Axsome Therapeutics (AXSM) Morgan Stanley 24th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 24th Annual Global Healthcare Conference summary
14 Sep, 2026R&D and innovation trends
China-originated innovation is increasing, with more early-stage products and third-party R&D vendors emerging as viable options, but overall R&D approach remains steady.
AI is integrated across commercial operations, sales analytics, document drafting, and CMC monitoring, driving efficiency and productivity.
AI supports sales reps but does not replace face-to-face interactions with healthcare professionals.
Regulatory and policy environment
IRA negotiations are the most significant policy factor, with potential impact starting in 2032; preparations include HEOR analysis and conservative peak sales modeling.
FDA interactions are stable, with three approved products and ongoing dialogue for additional marketing applications; AXS-12 is under review with a PDUFA date of May 1.
AUVELITY launch and performance
Q2 growth was driven mainly by MDD, with Q3 showing increasing impact from the Alzheimer's agitation indication.
NBRXs reached a new high, with the 65+ Medicare cohort growing from 19% to 31% of NBRXs post-approval.
Growth is in line with expectations, with new prescribers and positive real-world feedback supporting future utilization.
Plans are in place to provide more detailed launch metrics in upcoming quarters.
Latest events from Axsome Therapeutics
- AUVELITY momentum and an expanded pipeline underpin the next phase of growth.AXSM
UBS Global Biopharma Conference 2026 - AUVELITY momentum and a deep pipeline frame a $260M-revenue quarter.AXSM
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 52% as AUVELITY-led sales narrowed losses and pipeline milestones advanced.AXSM
Q3 2026 - Auvelity’s launch and pipeline expansion underpin an expected next phase of growth.AXSM
H.C. Wainwright 28th Annual Global Investment Conference - AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth.AXSM
12th Annual Cantor Fitzgerald Global Healthcare Conference - AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials.AXSM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue grew 46% to $218.4M, led by AUVELITY's Alzheimer's launch and pipeline progress.AXSM
Q2 2026 - Late-stage CNS pipeline targets high unmet needs with strong data and major commercial potential.AXSM
R&D Day 2025 - Symbravo gains FDA approval for acute migraine, offering rapid, sustained relief and broad market potential.AXSM
FDA Announcement